Price movement over the last 24 hours
AbCellera Biologics Inc vs Bilibili Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Bilibili Inc trades at $18.08 (market cap $7.28B). The key difference: Bilibili Inc is far larger — about 3.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BILI | |
|---|---|---|
Market Cap | $2.35B | $7.28B |
Sector | Health | Media |
52-Week High | $8.12 | $35.92 |
52-Week Low | $2.78 | $15.96 |
Enterprise Value | $1.99B | $5.13B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bilibili (BILI) trades at $17.90, up 4.43% today, with a bullish technical signal despite mixed moving average indicators. The company reported Q1 2026 EPS of $0.19, beating expectations, and maintains strong analyst support with 83% buy ratings. Recent news highlights a new $300 million share repurchase program and continued user growth, though revenue expansion remains moderate.
The outlook is positive given earnings beats and shareholder-friendly buybacks, but risks include competitive pressures in China's video platform market and reliance on advertising growth. Upside potential hinges on margin expansion and successful AI integration, while macroeconomic volatility poses a headwind.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →